Effective March 11, 2026, UnitedHealthcare consolidated universal minimum eligibility requirements for CAR T‑cell therapy to align with ASTCT expert guidance, emphasizing a multi‑system pre‑treatment assessment rather than standalone exclusion rules. Pulmonary evaluation — specifically dyspnea assessment and pulse oximetry — is now explicitly listed among required baseline assessments alongside renal (GFR/creatinine), hepatic (AST/ALT, bilirubin), and cardiac (LVEF) evaluations. Hematologic and neurologic baselines (ANC/ALC, platelets, neurologic exam) plus comorbidity factors such as autoimmune disease, immunosuppressive therapy, and active/uncontrolled infection are included as part of the unified eligibility considerations. The update does not provide numeric cutoffs or timing windows, but frames these measures as standard components of candidate risk assessment for CAR T‑cell therapy.
March 2026 Revision: Consolidated Universal Minimum Eligibility Requirements
This revision (effective 2026-03-11) clarifies the universal minimum eligibility requirements for CAR T-cell therapy as summarized from the ASTCT expert panel (Jain et al., 2019). The document explicitly lists organ system and baseline assessments that should be considered when evaluating candidates for CAR T-cell therapy, consolidating those considerations into a single section titled "Universal Minimum Eligibility Requirements."
No new CPT codes or policy numbers are introduced in the source text. The update emphasizes multi‑system assessment (renal, liver, cardiac, pulmonary, hematologic, neurologic) and comorbidity considerations (autoimmune conditions, immunosuppressive therapy, active/uncontrolled infection) as a unitary set of eligibility considerations rather than separate, disparate items.
Pulmonary Status: Dyspnea and Pulse Oximetry Included in Eligibility Assessment
Pulmonary status is expressly listed among the universal minimum eligibility considerations for CAR T-cell therapy. The policy identifies specific pulmonary parameters to be evaluated: presence or degree of dyspnea and measured oxygenation via pulse oximetry. These items are included alongside other organ function measures rather than as standalone exclusion criteria.
Within the document context, pulmonary assessment is presented as a critical component of the multi‑system pre‑treatment evaluation recommended by ASTCT (Jain et al., 2019). The policy text does not quantify thresholds (for example, specific oxygen saturation cutoffs) or define how pulmonary findings translate into eligibility determinations; it records pulmonary status as a key consideration to be assessed.
Other Organ Function Requirements: Renal, Hepatic, Cardiac Evaluations
In addition to pulmonary parameters, the policy enumerates other organ system evaluations considered part of the universal minimum eligibility requirements. These include renal function (GFR, ), liver function (, bilirubin), and cardiac status (). The document frames these laboratory and functional measures as integral to assessing a candidate's ability to tolerate CAR T-cell therapy.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.